Pegylated Interferon Alfa 2a — Competitive Intelligence Brief

Pegylated Interferon Alfa 2a (Pegylated Interferon Alfa 2a) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alpha. Area: Immunology, Virology, Oncology.

marketed Interferon alpha Interferon-alpha receptor (IFNAR) Immunology, Virology, Oncology Small molecule

Target snapshot

Pegylated Interferon Alfa 2a (Pegylated Interferon Alfa 2a) — Vertex Pharmaceuticals Incorporated. Pegylated Interferon Alfa 2a activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pegylated Interferon Alfa 2a TARGET	Pegylated Interferon Alfa 2a	Vertex Pharmaceuticals Incorporated	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Intron A	INTERFERON ALFA-2B	Merck & Co.	marketed	Interferon alpha		1986-01-01
Peginterferon alfa-2a with Ribavirin	Peginterferon alfa-2a with Ribavirin	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	Interferon alpha with nucleoside analog	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Placebo and peginterferon	Placebo and peginterferon	National Taiwan University Hospital	marketed	Interferon alpha (pegylated)	Interferon-alpha receptor (IFNAR)
Peg-IFN α-2b combined with NAs	Peg-IFN α-2b combined with NAs	Shenzhen Third People's Hospital	marketed	Interferon alpha combined with nucleos(t)ide reverse transcriptase inhibitor	Interferon-alpha receptor (IFNAR); HBV reverse transcriptase
Pegylated Interferon alpha-2a	Pegylated Interferon alpha-2a	ANRS, Emerging Infectious Diseases	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Peginterferon alfa-2a 40KD and Ribavirin	Peginterferon alfa-2a 40KD and Ribavirin	NORDynamIC Study Group	marketed	Interferon alpha with nucleoside analog	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alpha class)

1. Dr. Conrado Fernandez · 2 drugs in this class
2. Ain Shams University · 1 drug in this class
3. Beijing 302 Hospital · 1 drug in this class
4. Foundation for Liver Research · 1 drug in this class
5. Hoffmann-La Roche · 1 drug in this class
6. Kexing Biopharm Co., Ltd. · 1 drug in this class
7. Merck & Co. · 1 drug in this class
8. ANRS, Emerging Infectious Diseases · 1 drug in this class
9. Vertex Pharmaceuticals Incorporated · 1 drug in this class